Merck Presents New MAVENCLAD® (Cladribine Tablets) Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation
Business Wire India New data showed sustained reduction in neurofilament light chain (NfL) levels over two years of treatment with MAVENCLAD® (cladribine tablets) in patients with relapsing multiple sclerosis (RMS)…